Sign up here for GlobalData's free bi-weekly Covid-19 report on the latest information your industry needs to know.UK-based gene and cell therapy group Oxford Biomedica has entered a supply agreement with AstraZeneca UK for large-scale production of Covid-19 vaccine candidate, AZD1222.
The 18-month supply deal is part of a three-year master supply and development agreement between the companies, which may choose to expand the supply period for an additional 18 months into 2022 and 2023.
According to the agreement, AstraZeneca will make an upfront payment of £15m to Oxford Biomedica as a capacity reservation fee.
Based on manufacturing scale-up and continuation of the vaccine programme, Oxford Biomedica may get additional payments in excess.